Effects of kynurenine pathway inhibition on NAD + metabolism and cell viability in human primary astrocytes and neurons

International Journal of Tryptophan Research

Volumn 4, Issue 1, 2011, Pages 29-37

  Braidy, Nady ^a   Guillemin, Gilles J ^a,b   Grant, Ross ^a,c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b St Vincent's Centre for Applied Medical Research   (Australia)

^c SYDNEY ADVENTIST HOSPITAL   (Australia)

Author keywords

Astrocytes neurons 1 MT; Ido; Nad+; Sirtuins

Indexed keywords

EID: 84859741613     PISSN: None     EISSN: 11786469     Source Type: Journal    
DOI: 10.4137/IJTR.S7052     Document Type: Article

References (50)

1. Stone TW. Kynurenines in the CNS: from endogenous obscurity to therapeutic importance. Prog Neurobiol. 2001;64:185-218.
2. Stone TW. Purines and neuroprotection. Adv Exp Med Biol. 2002;513:249-80.
3. Heyes MP. The kynurenine pathway and neurologic disease. Therapeutic strategies. Adv Exp Med Biol. 1996;398:125-9.
4. Tuppo EE, Arias HR. The role of inflammation in Alzheimer's disease. Int J Biochem Cell Biol. 2005;37:289-305.
5. Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol. 2005;57:67-81.
6. Stone TW. Development and therapeutic potential of kynurenic acid and kynurenine derivatives for neuroprotection. Trends Pharmacol Sci. 2000;21: 149-54.
7. Stone TW. Endogenous neurotoxins from Tryptophan. Toxicon. 2001;39: 61-73.
8. Stone TW, Addae JI. The pharmacological manipulation of glutamate receptors and neuroprotection. Eur J Pharmacol. 2002;447:285-96.
9. Stone TW, Forrest CM, Mackay GM, Stoy N, Darlington LG. Tryptophan, adenosine, neurodegeneration and neuroprotection. Metab Brain Dis. 2007.
10. Stone TW, Mackay GM, Forrest CM, Clark CJ, Darlington LG. Tryptophan metabolites and brain disorders. Clin Chem Lab Med. 2003;41:852-9.
11. Guillemin GJ, Brew BJ. Implications of the kynurenine pathway and quinolinic acid in Alzheimer's disease. Redox Rep. 2002;7:199-206.
12. Guillemin GJ, Brew BJ, Noonan CE, Knight TG, Smythe GA, Cullen KM. Mass spectrometric detection of quinolinic acid in microdissected Alzheimer's disease plaques. In International Congress Series (Takai K, ed.^editors.). 2007;404-8.
13. Guidetti P, Hemachandra Reddy P, Tagle DA, Schwarcz R. Early kynurenergic impairment in Huntington's Disease and in a transgenic animal model. Neurosci Lett. 2000;283:233-5.
14. Guidetti P, Schwarcz R. 3-Hydroxykynurenine and quinolinate: pathogenic synergism in early grade Huntington's disease? Adv Exp Med Biol. 2003;527:137-45.
15. Guillemin GJ, Meininger V, Brew BJ. Implications for the kynurenine pathway and quinolinic acid in amyotrophic lateral sclerosis. Neurodegener Dis. 2005;2:166-76.
16. Brew BJ, Pemberton L, Evans L, Heyes M. Quinolinic acid production by macrophages infected with demented and non-demented isolates of HIV. Clin Neuropathol. 1993;12:S1.
17. Guillemin GJ, Wang L, Brew BJ. Quinolinic acid selectively induces apoptosis of human astocytes: Potential role in AIDS dementia complex. Journal of Neuroinflammation. 2005;2:16.
18. Guillemin GJ, Kerr SJ, Pemberton LA, et al. IFN-beta1 induces kynurenine pathway metabolism in human macrophages: Potential implications for multiple sclerosis treatment. Journal of Interferon and Cytokine Research. 2001;21:1097-101.
19. Stone TW, Darlington LG. Endogenous kynurenines as targets for drug discovery and development. Nat Rev Drug Discov. 2002;1:609-20.
20. Dale WE, Dang Y, Brown O. Tryptophan metabolism through kynurenine pathway in rat brain and liver slices. Free Radic Biol Med. 2000;29:191-8.
21. Braidy N, Grant R, Brew BJ, Adams S, Jayasena T, Guillemin GJ. Effects of Kynurenine pathway metabolites on intracellular NAD? synthesis and cell death in human primary astrocytes and neurons. IJTR. 2009;2:61-9.
22. Tan PH, Bharath AK. Manipulation of indoleamine 2,3 dioxygenase; a novel therapeutic target for treatment of diseases. Exp Opin Ther Targ. 2009;13: 987-1012.
23. Wonodi I, Schwarcz R. Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in schizophrenia. Schiz Bull. 2010;36: 211-8.
24. Braidy N, Grant R, Adams S, Brew BJ, Guillemin G. Mechanism for quinolinic acid cytotoxicity in human astrocytes and neurons. Neurotox Res. 2009;16:77-86.
25. Grant RS, Kapoor V. Murine glial cells regenerate NAD, after peroxideinduced depletion, using either nicotinic acid, nicotinamide, or quinolinic acid as substrates. J Neurochem. 1998;70:1759-63.
26. Berger SJ, Sudar DC, Berger NA. Metabolic consequences of DNA damage: DNA damage induces alterations in glucose metabolism by activation of Poly(ADP-ribose) polymerase. Biochem Biophys Res Commun. 1986;134: 227-32.
27. Erdelyi K, Bakondi E, Gergely P, Szabo C, Virag L. Pathophysiologic role of oxidative stress-induced poly(ADP-ribose) polymerase-1 activation: focus on cell death and transcriptional regulation. Cell Mol Life Sci. 2005; 62:751-9.
28. Bouchard V, Rouleau M, Poirier GG. PARP-1, a determinant of cell survival in response to DNA damage. Experimental Hematology. 2003;31:446-54.
29. Milne J, Denu JM. The Sirtuin family: Therapeutic targets to treat diseases of aging. Curr Pharm Des. 2008;12:11-7.
30. Anastasiou D, Krek W. SIRT1: linking adaptive cellular responses to agingassociated changes in organismal physiology. Physiology (Bethesda). 2006; 21:404-10.
31. Guillemin GJ, Brew BJ, Noonan CE, Takikawa O, Cullen KM. Indoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer's disease hippocampus. Neuropathol Appl Neurobiol. 2005;31:395-404.
32. Guillemin GJ, Kerr SJ, Smythe GA, et al. Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J Neurochem. 2001;78:1-13.
33. Bernofsky C, Swan M. An improved cycling assay for nicotinamide adenine dinucleotide. Anal Biochem. 1973;53:452-8.
34. Koh JY, Choi DW. Quantitative determination of glutamate mediated cortical neuronal injury in cell culture by lactate dehydrogenase efflux assay. J Neurosci Methods. 1987;20:83-90.
35. Takikawa O, Yoshida R, Kido R, Hayaishi O. Tryptophan degradation in mice initiated by indoleamine 2,3-dioxygenase. J Biol Chem. 1986;261: 3648-53.
36. Rahman A, Ting K, Cullen KM, Brew BJ, Braidy N, Guillemin GJ. The excitotoxin quinolinic acid induces tau phosphorylation in human neurons. PLOSONE. 2009;4:e6344.
37. Bradford MM. A rapid and sensitive method for quantitation of microgram quantities of protein utilising the principle of protein-dye binding. Anal Biochem. 1976;53:452-8.
38. Pallas M, Verdaguer E, Tajes M, Gutierrez-Cuesta J, Camins A. Modulation of sirtuins: new targets for antiageing. Recent Patents CNS Drug Discov. 2008;3:61-9.
39. +/NADPH in cellular functions and cell death: regulation and biological consequences. Antioxid Redox Signal. 2008;10:179-205.
40. + depletion. Cell Physiol Biochem. 2007;20:45-54.
41. + anabolism: Therapeutic potential for oxidative stress in ageing and Alzheimer's disease. Neurotox Res. 2007;13:173-84.
42. Grant RS, Naif H, Espinosa M, Kapoor V. IDO induction in IFN-gamma activated astroglia: a role in improving cell viability during oxidative stress. Redox Rep. 2007;5:101-4.
43. Grant R. Kynurenine pathway metabolism is involved in the maintenance of the intracellular NAD+ concentration in human primary astrocytes. IJTR. 2010;3:151-6.
44. + synthesis. Adv Enzymol Relat Areas Mol Biol. 2010;73:135-82, xi.
45. Kwidzinski E, Bechmann I. IDO expression in the brain: a double-edged sword. J Mol Med. 2007.
46. Sakurai K, Zou JP, Tschetter JR, Ward JM, GM S. Effect of indoleamine 2,3-dioxygenase on induction of experimental autoimmune encephalomyelitis. J Neuroimmunol. 2002;129:186-96.
47. Foster AC, Schwarcz R. Characterization of quinolinic acid phosphoribosyltransferase in human blood and observations in Huntington's disease. J Neurochem. 1985;45:199-205.
48. Guillemin GJ, Smythe G, Takikawa O, Brew BJ. Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia. 2005;49:15-23.
49. Fiege J, Auwerx J. Transcriptional targets of sirtuins in the coordination of mammalian physiology. Curr Opin Cell Biol. 2005:20.
50. Michishita E, Park J, Burneskis J, Barrett J, Horikawa I. Evolutionary conserved and nonconserved cellular localisations and functions of human SIRT proteins. Mol Biol Chem. 2005;16:4623-35.